Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis

Bioorg Med Chem Lett. 2023 Feb 15:82:129155. doi: 10.1016/j.bmcl.2023.129155. Epub 2023 Jan 30.

Abstract

We report the design, synthesis, and biological activity of a series of compounds that exhibit potent mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) inhibition. Structural transformation of the substructures of a starting compound gave amidomethyl derivatives and sulfonylguanidine derivatives that exhibited potent inhibition of MALT1. Compound 37 had good oral bioavailability and showed anti-psoriatic activity in an imiquimod-induced psoriasis mouse model after oral administration.

Keywords: MALT1 inhibitors; Psoriasis; Structure activity relationship.

MeSH terms

  • Animals
  • Lymphoma, B-Cell, Marginal Zone*
  • Mice
  • Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein
  • Psoriasis* / chemically induced
  • Psoriasis* / drug therapy

Substances

  • Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein
  • Malt1 protein, mouse